Consultation on this guideline raised concerns about the capacity in primary care to manage any potential increase in testing or diagnosis arising from increased risk assessment. This was acknowledged by the guideline group, with the understanding that primary care resourcing was outwith the remit of the guideline. The emerging developments in point-of-care testing in community pharmacies and the future ability to use home testing kits for HbA1c may offer possible solutions to the testing capacity pressures, together with investment in weight management, and type 2 diabetes prevention and remission programmes.
The implementation of Community Treatment and Care (CTAC) services can support the impact of increased testing. CTAC services are designed and configured around local population need and include basic disease data collection (eg blood pressure) and chronic disease monitoring. Learning for implementation is available from (https://ihub.scot/improvement-programmes/primary-care/community-treatment-and-care/about-community-treatment-and-care/)
The Scottish Government has published a national consensus statement with criteria for the prioritisation of use of GLP-1 RAs/GIP RAs in the treatment of people with obesity in NHS Scotland. It recommends that health boards adopt a phased introduction, initially for adults living with severe obesity and related cardiometabolic conditions. As part of the phased introduction, the consensus statement sets an initial eligibility threshold of body mass index (BMI) ≥38kg/m2 in the presence of at least one obesity-related health condition. By initially implementing a higher threshold, this will support health boards to embed appropriate care pathways and facilitate a gradual and more manageable progression towards the SMC criteria.